Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon/rectum, thyroid, and prostate: With a brief literature review

Table 1 Demographic features of patients with incidental focal hypermetabolism in colon/rectum, thyroid, and prostate

Lesion	Status	Men, n, (age, yr, mean ± SD)	Women, n, (age, yr, mean ± SD)	Total, n, (age, yr, mean ± SD)
Colon/rectum	Malignant	17 (70.5 ± 11.1)	8 (72.5 ± 14.1)	25 (70.8 ± 12.0)
	Premalignant	22 (68.1 ± 6.3)	7 (67.6 ± 17.4)	29 (67.9 ± 9.9)
	Benign	9 (60.7 ± 14.3)	22 (58.7 ± 14.6)	31 (59.3 ± 14.3)
Thyroid	Malignant	10 (61.1 ± 13.1)	19 (58.7 ± 10.7)	29 (59.8 ± 11.1)
	Benign	2 (67.5 ± 16.3)	17 (61.2 ± 13.1)	19 (61.9 ± 13.1)
Prostate	Malignant	22 (74.1 ± 7.7)	N/A	N/A
	Benign	17 (68.8 ± 6.1)	N/A	N/A

SD: Standard deviation.

Table 2 AUCs and cutoffs for malignant colorectal¹, thyroid, and prostate lesions

Lesion	SUV	AUC	95% confidence interval	P value	Cutoff	Sensitivity	Specificity
Colorectal	SUVmax	0.752	0.649-0.856	P < 0.001	7.6	0.673	0.676
	SUVpeak	0.729	0.62-0.836	P < 0.001	6.2	0.673	0.706
Thyroid	SUVmax	0.676	0.521-0.832	P = 0.025	6.9	0.63	0.632
Prostate	SUVmax	0.706	0.544–0.868	P = 0.026	3.8	0.591	0.588

¹Focal colorectal uptake includes both malignant and premalignant lesions.

AUC: Area under the curve; SUV: Standardized uptake value.